PDE4 inhibitors 1999
- 1 August 1999
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 9 (8) , 1101-1118
- https://doi.org/10.1517/13543776.9.8.1101
Abstract
The search for novel phosphodiesterase Type 4 (PDE4) inhibitors remains one of the most active fields within the pharmaceutical industry. Recent progress within the clinical development of PDE4 inhibitors has seen two more compounds progress to Phase III development. However, both Ariflo™ (SB-207499) and roflumilast are being developed principally for the treatment of chronic obstructive pulmonary disease (COPD) rather than asthma. This review also highlights the novel structural classes of PDE4 inhibitors disclosed in the past year’s patent applications and the concentration of effort on the identification of selective PDE4D inhibitors.Keywords
This publication has 14 references indexed in Scilit:
- Expired Nitric Oxide and Airway Obstruction in Asthma Patients with an Acute ExacerbationAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Substituted furans as inhibitors of the PDE4 enzymeBioorganic & Medicinal Chemistry Letters, 1999
- Dual Inhibition of Phosphodiesterase 4 and Matrix Metalloproteinases by an (Arylsulfonyl)hydroxamic Acid TemplateJournal of Medicinal Chemistry, 1999
- Thalidomide analogs and PDE4 inhibitionBioorganic & Medicinal Chemistry Letters, 1998
- Novel Cyclic Compounds as Potent Phosphodiesterase 4 InhibitorsJournal of Medicinal Chemistry, 1998
- PDE4 inhibitors 1998Expert Opinion on Therapeutic Patents, 1998
- TNF-α inhibitors and rheumatoid arthritisExpert Opinion on Therapeutic Patents, 1998
- 1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of AsthmaJournal of Medicinal Chemistry, 1998
- Phosphodiesterase IsozymesAmerican Journal of Respiratory and Critical Care Medicine, 1998
- COPD: New developments and therapeutic opportunitiesDrug News & Perspectives, 1998